ResMed Inc Stock News

Investing in defensive stocks like ResMed Inc. (RMD), Encompass Health Corporation (EHC), New Jersey Resources Corporation (NJR) and Global Water Resources, Inc. (GWRS) would be a wise idea during the

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

These companies saw their stocks spike after impressively beating earnings expectations last week and more upside could be ahead considering EPS estimates for fiscal 2024 have trended higher afterward

ResMed (RMD) could produce exceptional returns because of its solid growth attributes.

Although the latest Personal Consumption Expenditure (PCE) data showed inflation persisting in March, strong earnings reports from several big tech firms helped major U.S. equities indexes pop higher

ResMed easily beat Wall Street's earnings estimates for its fiscal Q3. The company's products are enjoying strong demand.

ResMed's (RMD) fiscal 2024 third-quarter performance reflects another strong period of execution across the entire business, resulting in impressive top and bottom-line growth.

The medical devices company beat expectations for its fiscal third quarter.

ResMed Inc. (NYSE:RMD ) Q3 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Amy Wakeham - Chief Communications and Investor Relations Officer Mick Farrell - Chief Executive

While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to

ResMed (RMD) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $1.92 per share. This compares to earnings of $1.68 per share a year ago.

ResMed beat Wall Street estimates for quarterly profit on Wednesday due to strong demand for its sleep apnea devices, sending shares 9% higher in extended trading.

Here is a sneak peek into how the three major MedTech stocks, LH, EW and RMD, are expected to fare in their quarterly results slated to be released tomorrow.

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

One of the pharmaceutical giant's hotter medications tested well for a new indication. It has already attracted much attention for the molecule being studied, as it's used in two FDA-approved treatmen